Efficacy of Low-Dose Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

被引:6
|
作者
Kim, Youlim [1 ]
Kim, Hyung-Sook [2 ]
Park, Jong Sun [3 ]
Cho, Young-Jae [3 ]
Yoon, Ho Il [3 ]
Lee, Sang-Min [4 ]
Lee, Jae Ho [3 ]
Lee, Choon-Taek [3 ]
Lee, Yeon Joo [3 ]
机构
[1] Hallym Univ, Chuncheon Sacred Heart Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Chuncheon Si 24253, Gangwon Do, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Pharm, Seongnam Si 13620, Gyeonggi Do, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seongnam Si 13620, Gyeonggi Do, South Korea
[4] Seoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 03080, South Korea
关键词
delirium; prevention; quetiapine; medical intensive care unit; extubation; INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; TERM COGNITIVE IMPAIRMENT; HALOPERIDOL PROPHYLAXIS; POSTOPERATIVE DELIRIUM; ELDERLY-PATIENTS; RISK; MORTALITY; DURATION; SURGERY;
D O I
10.3390/jcm9010069
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To evaluate the efficacy of short-term low-dose quetiapine for delirium prevention in critically ill patients. Methods: In this prospective, a single-center, randomized, double-blind, placebo-controlled trial, adult patients who were admitted from July 2015 to July 2017 to a medical intensive care unit (ICU) of a tertiary teaching hospital affiliated to Seoul National University were included. Quetiapine (12.5 mg or 25 mg oral at night; N = 16) or placebo (N = 21) was administered according to randomization until ICU discharge or the 10th ICU day. The primary endpoint was the incidence of delirium within the first 10 ICU days. Secondary endpoints included the rate of positive Confusion Assessment Method for the ICU (CAM-ICU) (the number of positive CAM-ICU counts/the number of total CAM-ICU counts), delirium duration, successful extubation, and overall mortality. Result: The incidence of delirium during the 10 days after ICU admission was 46.7% (7/15) in the quetiapine group and 55.0% (11/20) in the placebo group (p = 0.442). In the quetiapine group, the rate of positive CAM-ICU was significantly lower than in the placebo group (14.4% vs. 37.4%, p = 0.048), delirium duration during the study period was significantly shorter (0.28 day vs. 1.83 days, p = 0.018), and more patients in the quetiapine than in the placebo group were weaned from mechanical ventilation successfully (84.6% vs. 47.1%, p = 0.040). Conclusions: Our study suggests that prophylactic use of low-dose quetiapine could be helpful for preventing delirium in critically ill patients. A further large-scale prospective study is needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Analgesic efficacy of TENS therapy in patients with gonarthrosis A prospective, randomized, placebo-controlled, double-blind study
    Gschiel, B.
    Kager, H.
    Pipam, W.
    Weichart, K.
    Likar, R.
    SCHMERZ, 2010, 24 (05): : 494 - 500
  • [32] The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: A prospective, randomized, double-blind, placebo-controlled trial
    Crimi, E
    Liguori, A
    Condorelli, M
    Cioffi, M
    Astuto, M
    Bontempo, P
    Pignalosa, O
    Vietri, MT
    Molinari, AM
    Sica, V
    Della Corte, F
    Napoli, C
    ANESTHESIA AND ANALGESIA, 2004, 99 (03): : 857 - 863
  • [33] Efficacy of erythropoietin (R-HuEPO) in the critically ill patient: A randomized, double-blind, placebo-controlled trial
    Gettinger, A
    Corwin, HL
    Pearl, RG
    ANESTHESIOLOGY, 2002, 97 (03) : B11 - B11
  • [34] Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial
    Bruun, Karin Due
    Amris, Kirstine
    Vaegter, Henrik Bjarke
    Blichfeldt-Eckhardt, Morten Rune
    Holsgaard-Larsen, Anders
    Christensen, Robin
    Toft, Palle
    TRIALS, 2021, 22 (01)
  • [35] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED COMPARISON OF THE METABOLIC EFFECTS OF LOW-DOSE HYDROCHLOROTHIAZIDE AND INDAPAMIDE
    ELLIOTT, WJ
    WEBER, RR
    MURPHY, MB
    JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (08): : 751 - 757
  • [36] Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial
    Karin Due Bruun
    Kirstine Amris
    Henrik Bjarke Vaegter
    Morten Rune Blichfeldt-Eckhardt
    Anders Holsgaard-Larsen
    Robin Christensen
    Palle Toft
    Trials, 22
  • [37] Double-blind, placebo-controlled study of quetiapine in bipolar depression
    Calabrese, JR
    Macfadden, W
    McCoy, R
    Minkwitz, M
    Wilson, E
    Mullen, J
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S92 - S92
  • [38] Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies
    Milito, Cinzia
    Pulvirenti, Federica
    Cinetto, Francesco
    Lougaris, Vassilios
    Soresina, Annarosa
    Pecoraro, Antonio
    Vultaggio, Alessandra
    Carrabba, Maria
    Lassandro, Giuseppe
    Plebani, Alessandro
    Spadaro, Giuseppe
    Matucci, Andrea
    Fabio, Giovanna
    Dellepiane, Rosa Maria
    Martire, Baldassarre
    Agostini, Carlo
    Abeni, Damiano
    Tabolli, Stefano
    Quinti, Isabella
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (02) : 584 - +
  • [39] Aripiprazole for prevention of delirium in the neurosurgical intensive care unit: a double-blind, randomized, placebo-controlled study
    Mokhtari, Majid
    Farasatinasab, Maryam
    Machian, Mina Jafarpour
    Yaseri, Mehdi
    Ghorbani, Mohammad
    Hashemi, Seyed Mahmood Ramak
    Nikoobakht, Mehdi
    Golchin, Navid
    Mohammadi, Gholamhasan
    Sistanizad, Mohammad
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (04) : 491 - 499
  • [40] Aripiprazole for prevention of delirium in the neurosurgical intensive care unit: a double-blind, randomized, placebo-controlled study
    Majid Mokhtari
    Maryam Farasatinasab
    Mina Jafarpour Machian
    Mehdi Yaseri
    Mohammad Ghorbani
    Seyed Mahmood Ramak Hashemi
    Mehdi Nikoobakht
    Navid Golchin
    Gholamhasan Mohammadi
    Mohammad Sistanizad
    European Journal of Clinical Pharmacology, 2020, 76 : 491 - 499